Back to Agenda
[V6-S1] Industry-Academia-Government Collaboration Schemes in Japan
Session Chair(s)
Toichi Takenaka
Chairman
Japan Health Sciences Foundation, Japan
The Japan Agency for Medical Research and Development (AMED) was established two years ago. In order to minimize the boundaries of the industry, academia, and government in drug research, we host grant programs such as: the Department of Innovative Drug Discovery and Development (iD3) which is the first public program in Japan to deliver drug seeds from academia to clinical application, the GAPFREE program which grants public-private joint clinical research, and the Cyclic Innovation for Clinical Empowerment (CiCLE) which began in FY2017 to fund infrastructure and open innovation for medical needs based on industry-academia-government collaboration. Through these programs, we would like to discuss about the perspectives of industry-academia-government collaboration.
Speaker(s)
Drug Discovery Support Network - Recent Development & Future Perspectives
Yoichi Kurebayashi, DVM, PhD
Japan Agency for Medical Research and Development (AMED), Japan
Senior Director
About the Funding for Research to Expedite Effective Drug Discovery by Government, Academia and Private Partnership (GAPFREE) Program
Kazuki Yasuda, MD
National Center for Global Health and Medicine, Japan
Department of Metabolic Disorder, Diabetes Research Center, Research Institute
Development of the Innovative Vaccine Technology Based on Nucleic Acid Encapsulated in Nanoparticle Supported by the Ciclic Innovation for Clinical Empowerment (CiCLE) Program
Fumihiko Takeshita, MD, PhD
Daiichi Sankyo Co., Ltd., Japan
Senior Director (R&D) / Vice President, Vaccine Research Laboratories
Have an account?